Two Patent Grants Add to Stem Cell Therapeutics Corp. Patent Portfolio and Expand Geographic Coverage of Key Stem Cell Techno...
July 27 2011 - 12:12PM
Marketwired
Stem Cell Therapeutics Corp. (TSX VENTURE: SSS) ("SCT" or the
"Company") is pleased to announce that it has received notification
of the issuance of two additional patents. The first entitled "Use
of Luteinizing Hormone (LH) and Chorionic Gonadotropin (hCG) for
Proliferation of Neural Stem Cells and Neurogenesis" and was
granted by the Australian Patent office; Patent number 2005211847.
The second is entitled "Production of Radial Glial Cells" and was
issued by the Canadian Intellectual Property Office; Patent number,
2,364,095.
The first patent expands the geographical coverage of SCT's core
neurogenesis technology for increasing neural stem cell numbers, or
neurogenesis, by using human chorionic gonadotropin (hCG). The
technology can be used either directly by administration of a
therapeutic dose of drug or in the laboratory to expand the numbers
of cells that would later be transplanted into a patient or an
animal to induce regeneration of neural tissue in the setting of
neurodegenerative disease. This patent is the basis for SCT's
NTx®-265 therapy.
The second patent protects our exclusive use of specific
compounds to induce neurogenesis by identifying radial glial cells
(RCGs) as a potentially key central cell type within the
neurogenesis process. During early growth RCGs function as neural
progenitors in the developing central nervous system (CNS). This
discovery and patent anticipates that proper maturation and
migration of neuronal precursors will require RCGs to recapitulate
development processes normally quiescent in the 'adult' mammalian
brain. Importantly, RCGs are expected to be crucial for the
regeneration of damaged or diseased central nervous system tissue.
Similar to the first patent, direct administration of drug or
expansion of cells for transplantation is protected in all CNS
neurodegenerative diseases and more specifically, Alzheimer's
disease, Multiple Sclerosis, Huntington's disease Amyotrophic
Lateral Sclerosis or Parkinson's disease.
"SCT's investment in, and commitment to these novel regenerative
medical therapies continues to yield an ever stronger and broader
patent portfolio.". Said Dr. Allen Davidoff, Chief Scientific
Officer of Stem Cell Therapeutics Corp. "We are pleased with the
steady growth of our patent portfolio during the recent past and
look forward to issuance of additional patents from our various
applications over the near future.
SCT's intellectual property portfolio continues to be a key
asset for the company and a coveted, industry-leading technology
asset in regenerative medicine. "
About Stem Cell Therapeutics Corp.: Stem Cell Therapeutics Corp.
is a public biotechnology company (TSX VENTURE: SSS) focused on the
development and commercialization of drug-based therapies to treat
central nervous system diseases. SCT is a leader in the development
of therapies that utilize drugs to stimulate a patient's own
resident stem cells. The Company's programs aim to repair brain and
nerve function lost due to disease or injury. The Company's
extensive patent portfolio of owned and licensed intellectual
property supports the potential expansion into future clinical
programs in numerous neurological diseases such as stroke,
traumatic brain injury, multiple sclerosis, Huntington's disease,
Alzheimer's disease, and ALS.
These securities have not been registered under the United
States Securities Act of 1933, as amended, or the securities laws
of any state, and may not be offered or sold within the United
States or to, or for the account or benefit of U.S. persons unless
an applicable exemption from U.S. registration requirements is
available.
Except for historical information, this press release may
contain forward-looking statements, which reflect the Company's
current expectation regarding future events. These forward-looking
statements involve risk and uncertainties, which may cause but are
not limited to, changing market conditions, the successful and
timely completion of clinical studies, the establishment of
corporate alliances, the impact of competitive products and
pricing, new product development, uncertainties related to the
regulatory approval process and other risks detailed from time to
time in the Company's ongoing quarterly and annual reporting.
Neither TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
Contacts: Stem Cell Therapeutics Corp. Dr. Allen Davidoff, PhD,
CSO 403-245-5495 ext.226 adavidoff@stemcellthera.com
www.stemcellthera.com
Sunvest Minerals Corp (TSXV:SSS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Sunvest Minerals Corp (TSXV:SSS)
Historical Stock Chart
From Jul 2023 to Jul 2024